Share proof-of-concept readout for personalized cancer vaccine program
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 May 2022
- Due
- 31 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“on our personalized cancer vaccine program this year”
What we found
Evidence strength A What the grades mean
Later 10-K filings state Moderna announced positive Phase 2 results for its personalized cancer vaccine mRNA-4157 in December 2022, within the stated 2022 period.
-
A Moderna 10-K filed 2023-02-24
“In December 2022, we announced positive Phase 2b results for mRNA-4157, our personalized cancer vaccine (PCV)” ✓ confirmed on the page
-
A Moderna 10-K filed 2024-02-23
“In December 2022, we announced that the randomized Phase 2 trial of mRNA-4157 had met its primary endpoint.” ✓ confirmed on the page
Market reaction: the shares moved -4.8% against the S&P 500 over the three sessions around the disclosure (23 Feb 2023 to 28 Feb 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Share
- Deliverable
- Proof-of-concept readout for personalized cancer vaccine program
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-MRNA-006185 · Corrections policy